Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Pci Biotech Holding Asa | LSE:0JGL | London | Ordinary Share | NO0010405640 | PCI BIOTECH HOLDING ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 51.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.99M | -20.32M | -0.5443 | -93.70 | 1.9B |
From Nov 2023 to Nov 2024
Oslo, 23 May 2024. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors.
Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 24 May 2024. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 4,288,185 additional shares. In total, Mr. Bøhn will represent and vote for 11.8 percent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 24 May 2024.
This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act.
Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Ronny Skuggedal, CEO/CFO, rs@pcibiotech.no, Mobile: +47 9400 5757
1 Year Pci Biotech Holding Asa Chart |
1 Month Pci Biotech Holding Asa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
